局限性临床淋巴结阳性乳腺癌可省略腋窝淋巴结清扫:美国国家癌症数据库分析
本研究基于美国国家癌症数据库2010—2016年数据,比较cN+ T1-2乳腺癌患者接受前哨淋巴结活检联合区域淋巴结放疗与腋窝淋巴结清扫(联合或不联合放疗)的生存结局。
要点
- cN+ T1-2乳腺癌行前哨淋巴结活检联合区域淋巴结放疗,5年总生存率88%。
- 该生存结局不劣于腋窝淋巴结清扫联合或不联合放疗。
- 研究期间前哨淋巴结活检联合放疗组和腋窝淋巴结清扫联合放疗组比例增加,单纯腋窝淋巴结清扫组减少。
核心结论
- 局限性cN+ T1-2乳腺癌患者接受 upfront 前哨淋巴结活检联合区域淋巴结放疗,其生存结局不劣于接受腋窝淋巴结清扫联合或不联合放疗者。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列分析,纳入2010—2016年cN+ T1-2乳腺癌患者,排除接受新辅助化疗、IV期或pN2-3疾病者。
主要发现
- cN+ SLNB/RNI组和cN+ ALND/RNI组患者数量在研究期间增加,而cN+ ALND/no RNI组减少(P < 0.001)。
- cN+ SLNB/RNI组中位阳性淋巴结数为1枚,cN+ ALND/RNI组和cN+ ALND/no RNI组均为2枚;中位检查淋巴结数分别为3枚、14枚和14枚(P < 0.001)。
- 中位随访57.9个月(范围0.8—114个月),三组2年总生存率分别为97%、97%和92%,5年总生存率分别为88%、86%和78%(P < 0.001)。
临床怎么用
- 对于局限性cN+ T1-2乳腺癌患者,可考虑以前哨淋巴结活检联合区域淋巴结放疗替代腋窝淋巴结清扫,以降低腋窝淋巴结清扫相关并发症。
- 需开展前瞻性研究评估局部区域控制及长期结局。
局限性
- 本研究为基于美国国家癌症数据库的回顾性分析,可能存在选择偏倚和未测量混杂因素。
- 原文未报告局部区域控制结局,需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: De-escalation of axillary surgery in breast cancer has progressively taken place when appropriate. Data supporting surgical de-escalation in patients with clinically node-positive (cN+) disease remains scarce. Here, survival among patients with cN+ T1-2 tumours undergoing sentinel lymph node biopsy (SLNB) and regional nodal irradiation (RNI) was investigated and compared with that among patients undergoing axillary lymph node dissection (ALND) with or without RNI. METHODS: The National Cancer Data Base was used to identify three groups of patients with cN+ tumours according to axillary management among those treated between 2010 and 2016: patients who underwent SLNB and RNI (cN+ SLNB/RNI group); those who had ALND and RNI (cN+ ALND/RNI group); and those who had ALND alone (cN+ ALND/no RNI group). Patients who underwent neoadjuvant chemotherapy, and those who had stage IV breast cancer or pN2-3 disease were excluded. RESULTS: A total of 12 560 patients met the inclusion criteria: 3030 in the cN+ SLNB/RNI, 5446 in the cN+ ALND/RNI, and 4084 in the cN+ ALND/no RNI group. The sizes of cN + SLNB/RNI and cN+ ALND/RNI groups increased over the study interval, whereas the cN+ ALND/no RNI group decreased in size (P < 0.001). There was a median of one positive node in the cN+ SLNB/RNI group and two nodes in the cN+ ALND/RNI and cN+ ALND/no RNI groups. The median number of nodes examined was three, 14, and 14, respectively (P < 0.001). Median follow-up was 57.9 (range 0.8-114) months. The overall survival rate was 97, 97, and 92 per cent respectively at two years, and 88, 86, and 78 per cent at five years (P < 0.001). CONCLUSION: Patients with limited cN+ T1-2 breast cancer undergoing upfront SLNB and RNI have favourable survival outcomes that are not inferior to those of patients undergoing ALND with or without RNI. Prospective studies are warranted to assess locoregional control and long-term outcomes. The surgical management of lymph node metastases in patients with breast cancer continues to change. To minimize the complications of extensive removal of axillary lymph nodes (axillary dissection), more limited surgery is now the standard of care when the cancer has not spread to the axillary lymph nodes. This study examined data from a large national cancer database in the USA. The results showed that patients with minimal lymph node metastases can also undergo less extensive axillary surgery without affecting survival, if surgery is combined with radiation therapy.
引用
- Cocco D, Shah C, Wei W, et al. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis. Br J Surg. 2022. PMID: 36066266. doi:10.1093/bjs/znac305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。